

**Amendments to the Claims**

Please amend the claims presently pending in the application and add new claims 30 and 31 as shown below in the list of claims.

**List of Claims**

- 1-16. Cancelled.
17. (Previously presented) A peptide with ferroxidase activity consisting essentially of the amino acid sequence of SEQ ID NO:7.
18. (Currently amended) ~~The peptide of claim 17, wherein said peptide is 23 amino acids in length~~ A peptide comprising the amino acid sequence of SEQ ID NO:7, wherein said peptide has ferroxidase enzymatic activity.
19. (Previously presented) The peptide of either claim 17 or claim 18, wherein said peptide is substantially pure.
20. (Currently amended) A pharmaceutical composition ~~in unit dose form~~ comprising a ~~therapeutically effective amount of~~ the peptide of either claim 17 or claim 18, together with a pharmaceutically acceptable carrier.
21. (Currently amended) The pharmaceutical composition of claim 20, wherein said pharmaceutical composition is in unit dose form and comprises 0.01-10 mg of said peptide.
22. (Previously presented) The pharmaceutical composition of claim 20, wherein said pharmaceutical composition is in the form of a liquid suitable for parenteral administration.

23. (Currently amended) The pharmaceutical composition of claim 20, wherein said pharmaceutical composition is indicated for use in ~~the treatment of~~ reducing oxidation-related damage in a patient suffering from stroke, heart attack, spinal injury or for administration to a patient undergoing surgery to reduce cellular injury resulting from oxidative stress.
24. (Previously presented) A peptide with ferroxidase activity consisting of the amino acid sequence of SEQ ID NO:7.
25. (Previously presented) The peptide of claim 24, wherein said peptide is substantially pure.
26. (Currently amended) A pharmaceutical composition ~~in unit dose form~~ comprising a ~~therapeutically effective amount of~~ the peptide of claim 24, together with a pharmaceutically acceptable carrier.
27. (Currently amended) The pharmaceutical composition of claim 26, wherein said pharmaceutical composition is in unit dose form and comprises 0.01-10 mg of said peptide.
28. (Previously presented) The pharmaceutical composition of either claim 26 or claim 27, wherein said pharmaceutical composition is in the form of a liquid suitable for parenteral administration.
29. (Currently amended) The pharmaceutical composition of claim 28, wherein said pharmaceutical composition is indicated for use in ~~the treatment of~~ reducing oxidation-related damage in a patient suffering from stroke, heart attack, spinal injury, or for administration to a patient before surgery to reduce cellular injury resulting from oxidative stress.

30. (New) A pharmaceutical composition in unit dose form comprising the peptide of either claim 17 or claim 18 together with a pharmaceutically acceptable carrier, wherein said peptide is present in a therapeutically effective amount for reducing oxidation-related damage in a patient suffering from stroke, heart attack, spinal injury, or for administration to a patient undergoing surgery to reduce cellular injury resulting from oxidative stress.
31. (New) A pharmaceutical composition in unit dose form comprising the peptide of claim 24 together with a pharmaceutically acceptable carrier, wherein said peptide is present in a therapeutically effective amount for reducing oxidation-related damage in a patient suffering from stroke, heart attack, spinal injury, or for administration to a patient undergoing surgery to reduce cellular injury resulting from oxidative stress.